Telix Pharmaceuticals

Telix reports that the imaging business generates around $1 billion in annual revenue and funds research and development. The company received FDA approval for PIXCLARA, expanding its commercial portfolio to three products and expects launch revenues of “a few hundred million” US dollars. Recruitment for the BiPASS phase-III study is complete, and three phase-III therapy programs are also recruiting, including ProstACT GLOBAL 2 with TLX591 and the novel TLX597. Management sees 2026 guidance toward the upper end of the range but remains cautious about making adjustments given the market environment. » Więcej na de.investing.com

Telix shares rose 10.3% to A$18.03 after the FDA approved the PET imaging agent Pixclara (floretyrosin F 18) to distinguish recurrent from progressive gliomas. The approval makes Telix the sole holder of an FDA‑approved radiopharmaceutical imaging agent for this indication. The approval opens significant commercial opportunities, as gliomas account for about 30% of brain and CNS tumors and roughly 80% of malignant brain tumors. Additional momentum came from management presentations at an investor conference; Telix reported H1 2026 revenue of USD 477 million (+22%), adjusted EBITDA up 146%, and raised its full‑year guidance to over USD 1 billion. » Więcej na de.investing.com

Telix presented at the Morgan Stanley Healthcare Conference an integrated strategy that links imaging diagnostics with therapeutic radiopharmaceuticals and seeks vertical control over manufacturing, logistics and patient selection. The company reported around AUD 1 billion in annual revenue, multiple approvals including Pixclara for gliomas, and named near-term catalysts such as the re-submission of Zircaix, completed recruitment of the BiPASS study and an interim analysis for TLX591. Telix is expanding its own nuclear pharmacies, acquired RLS to strengthen logistics, and sees significant growth potential in prostate cancer diagnostics as well as in late-stage programs for prostate, kidney and neurological indications. » Więcej na de.investing.com